TB Intensive San Antonio, Texas December 1-3, 2010

Similar documents
Tuberculosis Intensive

Tuberculosis Pathogenesis

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive Houston, Texas October 15-17, 2013

CHAPTER 3: DEFINITION OF TERMS

Fundamentals of Tuberculosis (TB)

Pathology of pulmonary tuberculosis. Dr: Salah Ahmed

TUBERCULOSIS. Pathogenesis and Transmission

Diagnosis and Medical Management of Latent TB Infection

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

What Drug Treatment Centers Can do to Prevent Tuberculosis

Contact Investigation San Antonio, Texas January 14-15, 2013

Transmission and Pathogenesis of Tuberculosis. Transmission and Pathogenesis of Tuberculosis. Mycobacteria. Introduction to the pathogen Transmission

Transmission and Pathogenesis of Tuberculosis

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Tuberculosis. By: Shefaa Q aqa

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Mycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Contact Investigation

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

Self-Study Modules on Tuberculosis

(b) Describe the role of antigen presentation in the body s specific immune response to infection by viruses. (4)

TUBERCULOSIS CONTACT INVESTIGATION

Contracts Carla Chee, MHS May 8, 2012

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Communicable Disease Control Manual Chapter 4: Tuberculosis

Why need to havetb Clearance. To Control and Prevent Tuberculosis

Tuberculosis Tools: A Clinical Update

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

INDEX CASE INFORMATION

Characteristics of Mycobacterium

SWABCHA Fact Sheet: Tuberculosis (TB)

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Learning Objectives: Case 1 11/12/2015. Tuberculosis: Focus on Transmission and Pathogenesis. TB: Some Important Terms

Technical Bulletin No. 172

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Tuberculosis & Refugees in Philadelphia

Northwestern Polytechnic University

American Thoracic Society

Interpretation of Chest Radiographs Paul Christensen, MD 10/21/09. Diagnostic Evaluation. Medical Evaluation & CXR Interpretation.

Tuberculosis Elimination: The Role of the Infection Preventionist

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

"GUARDING AGAINST TUBERCULOSIS AS A FIRST RESPONDER"

In the lungs, the organisms are taken up by macrophages and carried to lymph nodes. State one characteristic symptom of TB other than coughing.

TB Intensive San Antonio, Texas November 29-December 2, 2011

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB Transmission, Pathogenesis & Infection Control

"GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES"

Latent tuberculosis infection

TB Infection Control. Carol Staton, RN, BSN March 17, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

"GUARDING AGAINST TUBERCULOSIS IN INSTITUTIONAL FACILITIES"

Errors in Dx and Rx of TB

Mycobacteria & Tuberculosis PROF.HANAN HABIB & PROF ALI SOMILY DEPRTMENT OF PATHOLOGY, MICROBIOLOGY UNIT COLLEGE OF MEDICINE

Chapter 5 Treatment for Latent Tuberculosis Infection

Community pharmacy-based tuberculosis skin testing

Tuberculosis. Impact of TB. Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH)

LTBI: Who to Test & When to Treat

Who is at Risk of TB?

TB Program Management San Antonio, Texas November 5-7, 2008

Core Curriculum on Tuberculosis: What the Clinician Should Know

TB Prevention Who and How to Screen

Identifying TB co-infection : new approaches?

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

TUBERCULOSIS. By Dr. Najaf Masood Assistant Prof Pediatrics Benazir Bhutto Hospital Rawalpindi

LATENT TUBERCULOSIS. Robert F. Tyree, MD

결핵 전남대학교병원 호흡기내과 권용수

Respiratory System الفريق الطبي االكاديمي

Self-Study Modules on Tuberculosis

TUBERCULOSIS. Famous victims in their intellectual prime: Chopin, Paganini, Thoreau, Keats, Elizabeth Browning, Brontës

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Molecular Epidemiology of Extrapulmonary Tuberculosis

TB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology

Part I Tuberculosis (TB): the Once and Future Plague

#114 - Tuberculosis Update [1]

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

A look at medical factors that increase the risk for TB disease

Tuberculosis Procedure ICPr016. Table of Contents

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

TB in Corrections Phoenix, Arizona

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

CLINICAL FEATURES IN PULMONARY TUBERCULOSIS

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Tuberculosis and Biologic Therapies: Risk and Prevention

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Transcription:

TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor of Medicine University of Texas Health Science Center - Tyler at the Texas Center for Infectious Disease

Outcomes of Exposure No infection (70%) Infection (30%) Of infected persons - No disease [latent] (90%) - Primary TB (5%) - Reactivation [post-primary] TB (5%) Latent Tuberculosis Infection No symptoms or signs of infection NOT infectious Positive tuberculin skin test T-cells respond to mycobacterial antigens Chest x-ray may be normal, or show granulomata, pleural or parenchymal scarring

PRIMARY AND POST-PRIMARY DISEASE

Pathogenesis of Pulmonary Acquired Tuberculosis Primary Disease Inhalation of Droplet Nuclei Localization to mid and lower areas of lung Pneumonia Multiplication Pleurisy Dissemination Acute hematogenous disease Meningitis PRIMARY TUBERCULOSIS

PRIMARY TUBERCULOSIS PRIMARY TUBERCULOSIS

PRIMARY TUBERCULOSIS Pathogenesis of Pulmonary Acquired Tuberculosis Post-Primary Disease Inhalation of Droplet Nuclei Localization to mid and lower areas of lung Multiplication Dissemination (Silent Bacteremia) Localization in areas of high oxygen concentration Apex of lung Kidney Development of Immunity Bone Brain Organisms killed Organisms walled off

Pathogenesis of Pulmonary Acquired Tuberculosis Post-Primary Disease Inhalation of Droplet Nuclei Localization to mid and lower areas of lung Multiplication Dissemination (Silent Bacteremia) Localization in areas of high oxygen concentration Apex of lung Kidney Development of Immunity Bone Brain Active disease Organisms killed Organisms walled off POST-PRIMARY TB

Who is most likely to become infected by Mycobacterium tuberculosis? Increased exposure Reduced resistance INFECTIOUS PARTICLES Only particles with < 5 μm aerodynamic diameter (infectious droplet nuclei) containing 1-3 tubercle bacilli can initiate infection (larger particles captured by mucociliary defenses)

LIKELIHOOD OF INFECTION Efficacy of droplet nuclei production - Coughing, talking, singing Bacillary burden of source case - AFB+ patients 4 times more infectious than AFB- patients Duration of exposure Ventilation - Closed rooms, crowding RESISTANCE TO INFECTION Innate immunity - Alveolar macrophages - Natural killer cells are lymphocytes that can lyse infected macrophages without prior exposure to the pathogen

Resistance to progression of infection to disease Adaptive immunity - T-lymphocytes, not B cells and antibodies - Th1 response (interleukin-12, interferongamma) Genetic susceptibility - IL-12 receptor, IFN-gamma receptor GRANULOMA FORMATION

GRANULOMA FORMATION GRANULOMA FORMATION

GRANULOMA FORMATION Latent Tuberculosis Infection 1) Bacteria are dormant (metabolically inactive). They later start to divide for reasons that are not clear. 2) Bacteria are metabolically active and dividing, but infection is controlled by the immune system. Disease develops when immunity wanes. Recent data in animals favor this hypothesis.

Latent infection Disease Recent infection HIV infection Chest x-ray evidence of prior TB Underweight by >10% Intravenous drug use ATS-CDC. Am J Respir Crit Care Med 2000;161:S221 Latent infection Disease Disease Relative risk Silicosis 30 Jejunoileal bypass 27-63 Renal transplant 37 Head or neck cancer 16 Renal failure 10-25.3 Diabetes 2.0-4.1 Gastrectomy 2-5 ATS-CDC. Am J Respir Crit Care Med 2000;161:S221-S247

Latent infection Disease Lung cancer Hematologic cancers TNFα inhibitors Prednisone >15 mg, > 4 weeks Other immunosuppressive drugs Latent infection Disease Smoking Never Smoked OR 1 Current Smoker OR 2.73 Ever Smoked OR 2.69 Am J Respir Crit Care Med 2009;180:475-480.

Am J Respir Crit Care Med 2009;180:475-480. Latent infection Disease Passive Smoking RR 1.64 Am J Respir Crit Care Med 2009;180:475-480. Arch Intern Med 2010;170(3): 287-292.

Summary Exposure can result in no infection, infection without disease (LTBI), primary TB or reactivation (post-primary) TB Factors that increase likelihood of infection Intensity and duration of exposure AFB+ source cases Ineffective innate immunity Innate immunity Macrophages, natural killer cells Summary Progression of infection to disease Adaptive immunity; T-cells, Th1 responses, IL-12 and IFN-gamma Recent data suggest that bacteria divide actively during latency but are contained by the immune system Recent infection and decreased immunity increase the risk that infection progresses to disease